Pfizer’s smoking-cessation drug Chantix edged out GlaxoSmithKline’s nicotine patch NicoDerm CQ in a study published today. The study was funded by Pfizer, and it’s a bit of good news for a drug that’s seen U.S. sales fall sharply amid concerns about the drug’s side effects.
Oddly enough, we wouldn’t have heard about the study (it’s published [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment